Chiral and RadaHaim Form Strategic Partnership to Advance Organoid-Driven Research Innovation

Chiral is pleased to announce that it has entered into a strategic collaboration with RadaHaim, a leading innovator in standardized and scalable organoid technologies. This partnership establishes a long-term framework aimed at advancing intelligent, data-driven innovation across next-generation biological research.

By combining Chiral’s computational and workflow-oriented capabilities with RadaHaim’s expertise in organoid production, high-throughput assays, and automated evaluation systems, the two companies will work together to explore new ways to enhance scientific workflows, strengthen analytical pipelines, and accelerate the development of innovative research platforms.

The partnership framework includes intentions to:

• - Co-develop advanced AI-enabled analytical and decision-support capabilities optimized for organoid-based studies
• - Integrate automated, high-quality data-processing and imaging pipelines
• - Establish shared standards for data handling, reproducibility, evaluation, and security
• - Build pathways toward long-term global commercialization and ecosystem expansion

Both companies share a vision of creating solutions that elevate research productivity, enable more predictive biological insights, and set new standards for innovation across the life sciences. Chiral and RadaHaim will continue to refine the scope of the collaboration as the partnership progresses.

About RadaHaim

RadaHaim is a biotechnology company specializing in the standardization and scalable production of organoids and is dedicated to transforming organoid technology into practical solutions for research, discovery and precision medicine. https://radahaim.com

About Chiral Ltd.

With a mission to make computational research mainstream, Chiral Ltd. tackles the challenge that high costs, complexity, and specialized knowledge requirements often prevent researchers from fully utilizing the potential of computational methods, thereby limiting scientific progress. In this program, the company will develop the cloud platform and integrate the target applications. https://www.chiral.one